Market News Video
MNV MNV 10 Stocks Crossing Above Their 200 Day Moving Average
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

January 2018 Options Now Available For Johnson & Johnson (JNJ)
Thursday, November 30, 10:47 AM ET, by Market News Video Staff

Investors in Johnson & Johnson (JNJ) saw new options begin trading today, for the January ...

January 2018 Options Now Available For Pfizer (PFE)
Thursday, November 30, 10:48 AM ET, by Market News Video Staff

Investors in Pfizer Inc (PFE) saw new options become available today, for the January 2018 ...

JNJ a Top 25 Dividend Giant With $22.56B Held By ETFs
Monday, December 4, 7:24 AM ET, by Market News Video Staff

Johnson & Johnson (JNJ) has been named as a Top 25 ''Dividend Giant'' by ETF ...

MCK Crosses Above Key Moving Average Level
Monday, December 4, 10:54 AM ET, by Market News Video Staff

In trading on Monday, shares of McKesson Corp (MCK) crossed above their 200 day moving ...

Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick
Monday, December 4, 11:50 AM ET, by Market News Video Staff

A study of analyst recommendations at the major brokerages shows that Pfizer Inc (PFE) is ...

  More articles:  1 2 next »

ETFs Impacted by Merck Results on Friday Morning

By Market News Video Staff, Friday, October 29, 9:22 AM ET
Play Video: The Importance of ETFs

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

This morning, Merck (NYSE:MRK) announced third quarter earnings of 85 cents per share, ex-items, narrowly beating Wall Street estimates of 82 cents per share. Though, with the stock trading lower in the pre-market, it appears traders are more focused on the top line miss by the company. Revenue for the third quarter came in at $11.12 billion, just short of the consensus estimate of $11.24 billion.

Merck's news is sure to impact a number of ETFs heavily weighted towards the pharmaceutical giant. The Pharmaceutical HOLDRS ETF (NASDAQ:PPH) holds 18.47% of its portfolio in Merck, second only to Johnson & Johnson (NYSE:JNJ) and the Health Care Select Sector SPDR Fund (AMEX:XLV) holds 9.37% of its portfolio in Merck, the third largest holding behind Johnson & Johnson and Pfizer (NYSE:PFE). For a full list of ETFs holding shares of Merck, visit the ETFs Containing MRK page.


Register Today to be alerted when we launch, and we'll offer you a 20% discount on your first year of service! The ETF Channel Flexible Growth Investment Portfolio is designed to seek growth for investors anywhere and everywhere. The key to the program is our portfolio strategy allows us complete flexibility in terms of asset allocation as there are no predetermined guidelines as to the level of stocks, bonds, cash, regions, countries, sectors, commodities, or even asset classes in the portfolio! In short, this is a completely flexible portfolio designed to follow the performance trail wherever it leads us.

Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   ETFs   Growth   Johnson   Merck   NYSE   Pfizer   Revenue   SPDR   Sector   Street   This   alerted   allows   asset   beating   behind   billion   came   cents   commodities   designed   earnings   estimates   flexibility   follow   holding   holds   level   line   list   lower   market   narrowly   number   portfolio   program   quarter   regions   second   sectors   share   short   third   towards   trading   visit   weighted   wherever   with   your
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Stock Message Boards Stock Market Definitions

ETFs Impacted by Merck Results on Friday Morning | Market News Video | Copyright © 2008 - 2017, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.